Novel antviral targets in Hepatitis C virus NS4B protein

丙型肝炎病毒 NS4B 蛋白的新抗病毒靶点

• 批准号: 7682256
• 负责人: Shirit Einav
• 金额: $ 13.06万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-15 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7682256
• 关键词: Affinity; Amino Acids; Antiviral Agents; Arginine; Binding; Biochemical; Cell membrane; Cells; Clinical; Communicable Diseases; Complement; Complex; Development; Dominant-Negative Mutation; Elements; Family; GTP Binding; GTP-Binding Proteins; Gene Expression Profile; Gene Expression Profiling; Genetic; Genome; Goals; Guanosine Triphosphate; Ha-ras Genes; Hepatitis C; Hepatitis C virus; Human; Hydrochloride Salt; Hydrolysis; Individual; Infection; Internet; Intracellular Membranes; Knowledge; Lead; Libraries; Life Cycle Stages; Light; Maintenance; Malignant - descriptor; Mediating; Membrane; Mentors; Microarray Analysis; Microfluidics; Molecular; Molecular Virology; Mus; Mutagenesis; Mutation; Nucleotides; Oligonucleotide Microarrays; Oncogenes; Patients; Pharmaceutical Preparations; Physicians; Play; Primary carcinoma of the liver cells; Process; Protein Family; Proteins; RNA Binding; RNA Recognition Motif; RNA Sequences; RNA Viruses; RNA replication; Research Design; Research Personnel; Resistance; Resources; Role; Sampling; Scientist; Sequence Analysis; Site; Structural Protein; Structure; Substrate Specificity; Training; Translating; Treatment Efficacy; Universities; Variant; Viral; Viral Genome; Viral Proteins; Viral hepatitis; Virus; Virus Replication; anti-hepatitis C; authority; base; career development; combat; design; effective therapy; high throughput screening; in vivo; inhibitor/antagonist; member; metaplastic cell transformation; novel; novel strategies; programs; replicase; resistance mechanism; tool; tumor; viral RNA

DESCRIPTION (provided by applicant): The proposal outlines a 5 year training plan to facilitate Dr. Einav's career development as an independent academic physician-scientist. Dr. Einav recently completed clinical training in infectious diseases at Stanford University. The proposed project takes advantage of outstanding technical and intellectual resources available at Stanford for the study of hepatitis C virus (HCV). Drs. Glenn and Quake who will serve as co-mentors for the project are both internationally recognized authorities on the molecular virology of HCV, and microfluidics, respectively. Current therapies are inadequate for most of the 170 million people infected with HCV worldwide. Our long-term objectives are to better understand the molecular virology of HCV and translate this knowledge into new antiviral strategies. This project's goal is to better understand non-structural 4B's (NS4B) role in HCV RNA replication and cellular transformation and enable the design of new anti-HCV strategies. Our overall hypothesis is that two different heretofore unrecognized functions of NS4B; nucleotide binding and hydrolysis and HCV RNA binding, are each essential for mediating NS4B's role in HCV replication, and the former is also essential for mediating NS4B's role in cellular transformation. Thus approaches designed to disrupt these functions may be potentially used to inhibit HCV replication. Pharmacologic inhibition of the nucleotide binding motif (NBM) may also inhibit the associated hepatoma. Our preliminary results suggest that NS4B binds and hydrolyzes GTP and binds HCV RNA. Genetically disrupting the conserved NBM and RNA binding domain impairs their biochemical activity and dramatically inhibits HCV replication. Furthermore, NS4B can mediate cellular transformation and tumor formation in mice independently of the Ha-ras gene. Specific aims and research design: 1) To characterize RNA binding by NS4B and its NBM by defining additional critical elements that mediate these functions and by determining the substrate specificity of the RNA binding. Biochemical analysis of RNA binding will be done using a novel microfluidics platform. 2) To define NS4B's role in HCV RNA replication by determining the genetic effects of disruption of the various elements of the NBM and RNA binding elements. 3) To define NS4B's role in malignant transformation by determining the role of the NBM in mediating this activity, by determining the role of NS4B in causing hepatoma in humans using sequence analysis, and by characterizing gene expression profiling in NS4B transformed clones. Taken together, more effective therapies are urgently needed against HCV, a major cause of viral hepatitis. We hope that this study will help translate our molecular virology findings into the development of new classes of anti-HCV agents. The latter could not only complement current drug cocktails, but by attacking novel targets would hopefully increase the therapeutic efficacy of the resulting combination.

描述（由申请人提供）：该提案概述了一项为期 5 年的培训计划，以促进 Einav 博士作为独立学术医师科学家的职业发展。 Einav 博士最近在斯坦福大学完成了传染病的临床培训。拟议的项目利用斯坦福大学提供的优秀技术和智力资源来研究丙型肝炎病毒（HCV）。博士。作为该项目联合导师的 Glenn 和 Quake 分别是 HCV 分子病毒学和微流体学领域国际公认的权威。目前的治疗方法对于全球 1.7 亿 HCV 感染者中的大多数来说是不够的。我们的长期目标是更好地了解 HCV 的分子病毒学，并将这些知识转化为新的抗病毒策略。该项目的目标是更好地了解非结构 4B (NS4B) 在 HCV RNA 复制和细胞转化中的作用，并帮助设计新的抗 HCV 策略。我们的总体假设是 NS4B 有两种迄今为止未被识别的不同功能：核苷酸结合和水解以及HCV RNA结合对于介导NS4B在HCV复制中的作用都是必需的，并且前者对于介导NS4B在细胞转化中的作用也是必需的。因此，旨在破坏这些功能的方法可能有可能用于抑制 HCV 复制。核苷酸结合基序（NBM）的药理抑制也可能抑制相关的肝癌。我们的初步结果表明 NS4B 结合并水解 GTP 并结合 HCV RNA。从基因上破坏保守的 NBM 和 RNA 结合域会损害它们的生化活性并显着抑制 HCV 复制。此外，NS4B 可以独立于 Ha-ras 基因介导小鼠的细胞转化和肿瘤形成。具体目标和研究设计： 1) 通过定义介导这些功能的其他关键元件并确定 RNA 结合的底物特异性，来表征 NS4B 及其 NBM 的 RNA 结合。 RNA 结合的生化分析将使用新型微流体平台进行。 2)通过确定NBM和RNA结合元件的各种元件的破坏的遗传效应来定义NS4B在HCV RNA复制中的作用。 3)通过确定NBM在介导该活性中的作用、通过使用序列分析确定NS4B在引起人类肝癌中的作用以及通过表征NS4B转化克隆中的基因表达谱来确定NS4B在恶性转化中的作用。总而言之，迫切需要更有效的治疗方法来对抗 HCV（病毒性肝炎的主要原因）。我们希望这项研究将有助于将我们的分子病毒学发现转化为新型抗 HCV 药物的开发。后者不仅可以补充现有的药物混合物，而且通过攻击新的靶点有望提高由此产生的组合的治疗效果。